Clinical Trials

April 16, 2025

Understanding how ROR1-targeted therapies work—and whether they apply to your specific blood cancer type—can help you make more informed treatment decisions.

October 23, 2024

Learn about tebapivat, a new anemia treatment in clinical trials for those with lower-risk MDS.

October 22, 2024

What is RVU120, a new medicine in clinical trials, and how may it help reduce signs/symptoms of AML, MDS, and myelofibrosis?

September 15, 2024

Promising new off-the-shelf CAR NK cell therapy, SENTI-202, offers hope for relapsed/refractory AML & MDS. Learn about eligibility and trial locations.

July 12, 2024

MDS specialist Harry Erba, MD, PhD, shared insight about a new treatment decision-making model for AML and MDS patients called myeloMATCH.

June 23, 2024

Luspatercept, also known as Reblozyl, is a medication used to treat MDS patients with anemia.

May 07, 2024

Discover Evorparcept's potential in high-risk MDS: ASPEN-02 study insights, safety, and treatment efficacy for patients seeking new options.

April 22, 2024

Delve into the benefits of clinical trials, such as access to the latest therapies and medical advancements, and navigate your treatment options wisely.

February 06, 2024

Early responses from the ven/aza combination treatment provided an effective avenue for patients to receive a stem cell transplant.

October 05, 2023

Imetelstat directly targets “malignant clones with abnormally high telomerase activity, enabling recovery of hematopoiesis (blood cell production).”